Modest Profitable Growth

Looking ahead, Tandem forecasts modest but profitable growth for 2026, projecting full‑year sales between $1.065 billion and $1.085 billion and gross margins of 56% to 57%. The company attributes its improving financials to a new pay‑as‑you‑go pharmacy model in the United States, which is shifting its revenue stream toward more predictable and higher‑margin recurring income.